APVO451 — IND submission
1H2027
Aptevo expects to enter Investigational New Drug ("IND") enabling studies for the lead candidate, APVO451, in 1H2027.Source filing
APVO biotech catalysts & pipeline
APTEVO THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
mipletamig — FDA meeting
1Q27
RAINIER has entered the final stage of dose optimization, positioning Aptevo to complete the Phase 1b RAINIER trial and select the recommended Phase 2 dose this year in anticipation of a Phase 2 regulatory interaction in 1Q27.Source filing